? PROTOCOL REVIEW AND MONITORING SYSTEM The Protocol Review and Monitoring System (PRMS) for the Tisch Cancer Institute (TCI) oversees all cancer related clinical research at Mount Sinai in order to ensure that it is of the highest scientific merit and that TCI resources are used efficiently. The PRMS consists of the Protocol Review and Monitoring Committee (PRMC) and the Scientific Progress and Accrual Review Committee (SPARC), a subcommittee of the PRMC. The PRMC review process ensures that all research is safe and scientifically sound with entry criteria that reflect our patient population, have a high probability of full accrual, do not compete with each other, have adequate resources to answer the question being asked, and is consistent with the priorities of the TCI. The SPARC review process monitors active protocols for continued scientific merit, progress, and accrual. Pre-PRMS evaluations are completed by the Disease Focus Groups (DFG) and the Data Safety and Monitoring Committee (DSMC). If applicable, protocols also receive a Resource Allocation Evaluation (RAE). The outcome from each of these evaluations is submitted to the PRMC for reference, ensuring that each protocol receives a thorough, high quality peer review. The PRMC review occurs prior to the submission to the Institutional Review Board (IRB). PRMS functions are independent of the IRB, and do not duplicate or overlap with the responsibilities of the IRB. The PRMS has the authority to open protocols that meet the scientific merit and priorities of the TCI and to terminate protocols that do not demonstrate scientific progress.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Hu, Liangyuan; Hogan, Joseph W; Mwangi, Ann W et al. (2018) Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection. Biometrics 74:703-713
Ferrara, James L M; Chaudhry, Mohammed S (2018) GVHD: biology matters. Hematology Am Soc Hematol Educ Program 2018:221-227
Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia et al. (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37:3740-3752
Mascarenhas, J; Virtgaym, E; Stal, M et al. (2018) Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol 97:1369-1374
Wu, Lisa M; Amidi, Ali; Valdimarsdottir, Heiddis et al. (2018) The Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors. J Clin Sleep Med 14:31-39
Miller, Albert; Szeinuk, Jaime; Noonan, Curtis W et al. (2018) Libby Amphibole Disease: Pulmonary Function and CT Abnormalities in Vermiculite Miners. J Occup Environ Med 60:167-173
Vuong, Linh T; Iomini, Carlo; Balmer, Sophie et al. (2018) Kinesin-2 and IFT-A act as a complex promoting nuclear localization of ?-catenin during Wnt signalling. Nat Commun 9:5304
Bickell, Nina A; Lin, Jenny J; Abramson, Sarah R et al. (2018) Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract 14:e23-e33
Li, Weiqiang; Middha, Mridu; Bicak, Mesude et al. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol 74:710-719
Nobre, Ana Rita; Entenberg, David; Wang, Yarong et al. (2018) The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol 28:941-956

Showing the most recent 10 out of 143 publications